Can we cure metastatic -mutated lung cancer today?
作者信息
Christopoulos Petros
机构信息
Department of Medical Oncology, Thoraxklinik and National Center for Tumor Diseases at Heidelberg University Hospital, Heidelberg, Germany.
Translational Lung Research Center at Heidelberg University Hospital, Member of the German Center for Lung Research (DZL), Heidelberg, Germany.
出版信息
Transl Cancer Res. 2023 Feb 28;12(2):209-212. doi: 10.21037/tcr-22-2926. Epub 2023 Feb 1.
Abstract
摘要
相似文献
1
Can we cure metastatic -mutated lung cancer today?如今我们能治愈转移性突变肺癌吗？
Transl Cancer Res. 2023 Feb 28;12(2):209-212. doi: 10.21037/tcr-22-2926. Epub 2023 Feb 1.
2
Tumor immune microenvironment in epidermal growth factor receptor-mutated non-small cell lung cancer before and after epidermal growth factor receptor tyrosine kinase inhibitor treatment: a narrative review.表皮生长因子受体酪氨酸激酶抑制剂治疗前后表皮生长因子受体突变的非小细胞肺癌中的肿瘤免疫微环境：一篇叙述性综述
Transl Lung Cancer Res. 2021 Sep;10(9):3823-3839. doi: 10.21037/tlcr-21-572.
3
Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.厄洛替尼治疗的 EGFR 外显子 19 突变型非小细胞肺癌患者的异质性耐药机制：持续存在的 FGFR3 突变、局部转化为 EGFR 突变型小细胞肺癌，以及获得性 T790M EGFR 突变。
Lung Cancer. 2017 Nov;113:14-17. doi: 10.1016/j.lungcan.2017.08.024. Epub 2017 Sep 1.
4
Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.表皮生长因子受体突变型非小细胞肺癌患者使用第一代表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）发生严重不良反应后切换使用第二代 EGFR-TKI 的临床影响。
Jpn J Clin Oncol. 2012 Jun;42(6):528-33. doi: 10.1093/jjco/hys042. Epub 2012 Mar 28.
5
Real-world treatment patterns of metastatic non-small cell lung cancer patients receiving epidermal growth factor receptor tyrosine kinase inhibitors.接受表皮生长因子受体酪氨酸激酶抑制剂治疗的转移性非小细胞肺癌患者的真实世界治疗模式。
Cancer Med. 2023 Jan;12(1):159-169. doi: 10.1002/cam4.4918. Epub 2022 Jun 15.
6
Clinical outcomes in patients with advanced epidermal growth factor receptor-mutated non-small-cell lung cancer in South Western Sydney Local Health District.悉尼西南部地方卫生区晚期表皮生长因子受体突变型非小细胞肺癌患者的临床结局
Intern Med J. 2017 Dec;47(12):1405-1411. doi: 10.1111/imj.13555.
7
Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Treatment and Salvage Chemotherapy in EGFR-Mutated Elderly Pulmonary Adenocarcinoma Patients.表皮生长因子受体（EGFR）-酪氨酸激酶抑制剂治疗及挽救性化疗用于EGFR突变的老年肺腺癌患者
Oncologist. 2015 Jul;20(7):758-66. doi: 10.1634/theoncologist.2014-0352. Epub 2015 Jun 8.
8
Rechallenge with previously administered epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis.在表皮生长因子受体酪氨酸激酶抑制剂治疗后出现脑膜转移的 EGFR 突变型非小细胞肺癌中重新挑战治疗。
Invest New Drugs. 2021 Dec;39(6):1732-1741. doi: 10.1007/s10637-021-01140-3. Epub 2021 Jul 14.
9
Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study.表皮生长因子受体酪氨酸激酶抑制剂治疗表皮生长因子受体突变型非小细胞肺癌患者的预测因素 - 一项多中心回顾性 SEQUENCE 研究。
Lung Cancer. 2017 Feb;104:58-64. doi: 10.1016/j.lungcan.2016.12.002. Epub 2016 Dec 14.
10
Clinical predictors of response to EGFR-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer: A real-world multicentric cohort analysis from India.表皮生长因子受体酪氨酸激酶抑制剂治疗表皮生长因子受体突变型非小细胞肺癌的临床预测因素：来自印度的真实世界多中心队列分析。
Curr Probl Cancer. 2020 Jun;44(3):100570. doi: 10.1016/j.currproblcancer.2020.100570. Epub 2020 Mar 20.
本文引用的文献
1
Long-term survival of a non-small cell lung cancer patient with -mutated brain metastases: a case report.一名患有EGFR突变脑转移的非小细胞肺癌患者的长期生存：病例报告
Transl Cancer Res. 2022 Dec;11(12):4448-4454. doi: 10.21037/tcr-22-1671.
2
Radiation Therapy for Brain Metastases: An ASTRO Clinical Practice Guideline.脑转移瘤放射治疗：ASTRO 临床实践指南。
Pract Radiat Oncol. 2022 Jul-Aug;12(4):265-282. doi: 10.1016/j.prro.2022.02.003. Epub 2022 May 6.
3
co-mutations as an independent prognostic factor in 2nd and further line therapy- mutated non-small cell lung cancer IV patients treated with osimertinib.共突变作为奥希替尼治疗的二线及后续治疗的突变型非小细胞肺癌IV期患者的独立预后因素。
Transl Lung Cancer Res. 2022 Jan;11(1):4-13. doi: 10.21037/tlcr-21-754.
4
Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion.实体瘤患者的体细胞基因组检测：ASCO 临时临床观点。
J Clin Oncol. 2022 Apr 10;40(11):1231-1258. doi: 10.1200/JCO.21.02767. Epub 2022 Feb 17.
5
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.一项比较奥希替尼联合贝伐珠单抗与奥希替尼单药二线治疗表皮生长因子受体（EGFR）阳性且获得性 T790M 突变的晚期非小细胞肺癌（NSCLC）的随机 II 期研究：欧洲胸部肿瘤平台（ETOP）10-16 BOOSTER 试验。
Ann Oncol. 2022 Feb;33(2):181-192. doi: 10.1016/j.annonc.2021.11.010. Epub 2021 Nov 26.
6
Defining oligometastatic non-small cell lung cancer: concept versus biology, a literature review.定义寡转移非小细胞肺癌：概念与生物学，文献综述
Transl Lung Cancer Res. 2021 Jul;10(7):3329-3338. doi: 10.21037/tlcr-21-265.
7
Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer.表皮生长因子受体（EGFR）突变型肺癌序贯靶向治疗的真实世界应用
Ther Adv Med Oncol. 2021 Mar 24;13:1758835921996509. doi: 10.1177/1758835921996509. eCollection 2021.
8
Earlier extracranial progression and shorter survival in ALK-rearranged lung cancer with positive liquid rebiopsies.液体活检呈阳性的ALK重排肺癌患者出现更早的颅外进展且生存期更短。
Transl Lung Cancer Res. 2021 May;10(5):2118-2131. doi: 10.21037/tlcr-21-32.
9
Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma.解析 ALK 和 EGFR 阳性肺腺癌中的免疫抑制性肿瘤微环境。
Cancer Immunol Immunother. 2022 Feb;71(2):251-265. doi: 10.1007/s00262-021-02981-w. Epub 2021 Jun 14.
10
Principles and Current Clinical Landscape of Multispecific Antibodies against Cancer.癌症多特异性抗体的原理和当前临床现状。
Int J Mol Sci. 2021 May 26;22(11):5632. doi: 10.3390/ijms22115632.
Zotero 插件